• Search
  • Helpdesk
  • Sales contact

Infography: planning an oncology study with eCOA/ePRO

21 February 2017

The FDA has provided guidance on methodology to be used for developing and using PRO in oncology drug development programmes, and has emphasized the increased importance on patient input in clinical trials. In addition to QoL, many PRO questionnaires are used to assess complementary areas in oncology study, including: disease related symptoms (pain or fatigue), physical/social/emotional aspects, symptomatic adverse events, and satisfaction with the care provided.

Using eCOA for oncology trials can be particularly challenging because of the range of therapeutic approaches. Key components should be taken into consideration in your oncology study to ensure the success of eCOA implementation.

To download the infography, click here:

[tag url=”https://kayentis.com/wp-content/uploads/2017/02/kayentis_infography_successful_oncology_study.pdf” event=”click onco infography”]

Capture d’écran 2017-02-21 à 14.31.14

 

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

Digital Biomarkers in Clinical Trials Summit

26 JUNE 2024 • ROCHE BUILDING 1 • BASEL
https://digitalbiomarkers.panagorapharma.com/    

Mobile in Clinical Trials

16 SEPT 2024 • Philadelphia, USA
https://mobileinclinicaltrials.com/

DPharm 2024

17-18 SEPT 2024 • Philadelphia, USA
https://dpharmconference.com/   

SCDM 2024

29 SEPT - 2 OCT 2024 • Boston, USA
https://scdmlive.org/annual-conference-2024/      

ISOQOL 2024

13-16 OCT 2024 • Cologne, Germany
https://www.isoqol.org/    

CNS SUMMIT 2024

10-13 NOV 2024 • Cologne, Germany
https://cnssummit.org/the-summit/  

DMB 2024

13 NOV 2024 • Paris, France
https://dmb-asso.org/

SCOPE 2025

FEB 3-6 2025 • Orlando, USA
Booth #931 https://www.scopesummit.com/